Status:
RECRUITING
FAPI PET for Lung Fibrosis
Lead Sponsor:
University of California, Los Angeles
Conditions:
Interstitial Lung Disease
Idiopathic Interstitial Pneumonias
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer ...
Detailed Description
ILD is a group of respiratory diseases that affect the interstitium of the lungs. A major problem is the highly variable course of fibrosing ILD: some patients remain stable without treatment, and oth...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Patients with ILD confirmed by CT at time of staging
- Patients who have initiated or will initiate a new ILD medication with 3 months of enrollment OR Patients who are scheduled to undergo tissue biopsy or surgery of the lung
- Patients are ≥ 18 years old at the time of the radiotracer administration
- Patient can provide written informed consent
- Exclusion criteria
- Patient is pregnant or nursing
- Patients with active infectious lung disease
- Patients not expected to comply with the protocol requirements, not able to understand or follow trial procedures
Exclusion
Key Trial Info
Start Date :
November 16 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05365802
Start Date
November 16 2021
End Date
December 1 2026
Last Update
July 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States, 90095